Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

scientific article published on 10 January 2018

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/ESMOOPEN-2017-000299
P932PMC publication ID5786925
P698PubMed publication ID29387480

P50authorAlberto BardelliQ28321691
Andrea Sartore-BianchiQ28321693
Salvatore SienaQ28321703
Vincenzo SforzaQ56953948
P2093author name stringFortunato Ciardiello
Anna Maria Rachiglio
Nicola Normanno
Teresa Troiani
Erika Martinelli
Davide Ciardiello
Giulia Martini
Silvia Marsoni
Pietro Paolo Vitiello
Claudia Cardone
P2860cites workActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabQ24600031
Comprehensive molecular characterization of human colon and rectal cancerQ24630415
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.Q27851711
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerQ27851787
HER2 activating mutations are targets for colorectal cancer treatmentQ27853193
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialQ27853380
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerQ28076490
EGFR antagonists in cancer treatmentQ29616740
ERBB receptors and cancer: the complexity of targeted inhibitorsQ29619520
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyQ38384113
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomasQ39013804
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trialQ45217739
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Q52861120
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.Q54279287
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.Q54343844
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.Q55080669
P433issue1
P921main subjectcolorectal cancerQ188874
metastatic colon cancerQ108566365
P304page(s)e000299
P577publication date2018-01-10
P1433published inESMO OpenQ53951848
P1476titleSequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
P478volume3

Reverse relations

cites work (P2860)
Q91754859Biomarker-guided therapy for colorectal cancer: strength in complexity
Q92522562Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
Q57183898Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status
Q64890286How I treat cancer special issue.
Q90017841Implementation of genomic medicine for gastrointestinal tumors
Q98386286Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer
Q92280751Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Q90513170Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
Q90711036Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
Q92747984Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer
Q54962247Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Search more.